387 related articles for article (PubMed ID: 34769400)
21. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Grillon A; Schramm F; Kleinberg M; Jehl F
PLoS One; 2016; 11(6):e0156690. PubMed ID: 27257956
[TBL] [Abstract][Full Text] [Related]
22. The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro.
Ebisuno S; Inagaki T; Kohjimoto Y; Ohkawa T
Cancer; 1997 Dec; 80(12):2263-7. PubMed ID: 9404703
[TBL] [Abstract][Full Text] [Related]
23. Conjugates of Ciprofloxacin and Levofloxacin with Cell-Penetrating Peptide Exhibit Antifungal Activity and Mammalian Cytotoxicity.
Ptaszyńska N; Gucwa K; Olkiewicz K; Heldt M; Serocki M; Stupak A; Martynow D; Dębowski D; Gitlin-Domagalska A; Lica J; Łęgowska A; Milewski S; Rolka K
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630159
[TBL] [Abstract][Full Text] [Related]
24.
Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
[TBL] [Abstract][Full Text] [Related]
26. Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line.
Aranha O; Wood DP; Sarkar FH
Clin Cancer Res; 2000 Mar; 6(3):891-900. PubMed ID: 10741713
[TBL] [Abstract][Full Text] [Related]
27. Ciprofloxacin-mediated induction of S-phase cell cycle arrest and apoptosis in COLO829 melanoma cells.
Beberok A; Wrześniok D; Minecka A; Rok J; Delijewski M; Rzepka Z; Respondek M; Buszman E
Pharmacol Rep; 2018 Feb; 70(1):6-13. PubMed ID: 29306115
[TBL] [Abstract][Full Text] [Related]
28. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
29. Comparative Assay of 2D and 3D Cell Culture Models: Proliferation, Gene Expression and Anticancer Drug Response.
Souza AG; Silva IBB; Campos-Fernandez E; Barcelos LS; Souza JB; Marangoni K; Goulart LR; Alonso-Goulart V
Curr Pharm Des; 2018; 24(15):1689-1694. PubMed ID: 29623827
[TBL] [Abstract][Full Text] [Related]
30. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Drugeon HB; Juvin ME; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
[TBL] [Abstract][Full Text] [Related]
31. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Drago L; Nicola L; Mattina R; De Vecchi E
BMC Microbiol; 2010 Apr; 10():119. PubMed ID: 20409341
[TBL] [Abstract][Full Text] [Related]
32. Cell Cycle Arrest and Apoptotic Effect of 7-(4-(N-substituted carbamoylmethyl) piperazin-1-yl) Ciprofloxacin-derivative on HCT 116 and A549 Cancer Cells.
Alaaeldin R; Nazmy MH; Abdel-Aziz M; Abuo-Rahma GEA; Fathy M
Anticancer Res; 2020 May; 40(5):2739-2749. PubMed ID: 32366419
[TBL] [Abstract][Full Text] [Related]
33. Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Bezwada P; Clark LA; Schneider S
Curr Med Res Opin; 2008 Feb; 24(2):419-24. PubMed ID: 18157922
[TBL] [Abstract][Full Text] [Related]
34.
Allen GP; Harris KA
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483960
[No Abstract] [Full Text] [Related]
35. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
36. Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro.
Mori K; Maru C; Takasuna K
J Pharm Pharmacol; 2000 May; 52(5):577-84. PubMed ID: 10864147
[TBL] [Abstract][Full Text] [Related]
37. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
[TBL] [Abstract][Full Text] [Related]
38. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
Sutton LD; Jones RN
J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
[TBL] [Abstract][Full Text] [Related]
39. Fluoroquinolone susceptibility testing of Salmonella enterica: detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin.
Sjölund-Karlsson M; Howie RL; Crump JA; Whichard JM
J Clin Microbiol; 2014 Mar; 52(3):877-84. PubMed ID: 24391204
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
Kang SL; Rybak MJ; McGrath BJ; Kaatz GW; Seo SM
Antimicrob Agents Chemother; 1994 Dec; 38(12):2702-9. PubMed ID: 7695250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
